exploring the approval of epcoritamab for diffuse large b-cell lymphoma with reid merryman, md
Published 1 year ago • 876 plays • Length 5:57Download video MP4
Download video MP3
Similar videos
-
5:36
investigating epcoritamab for follicular lymphoma and beyond with reid merryman, md
-
1:09
new dlbcl clinical trial: epcoritamab for diffuse large b-cell lymphoma
-
3:02
efficacy of epcoritamab and glofitamab in diffuse large b-cell lymphoma
-
1:22
ash23: reid merryman, md, on ct-dna & diffuse large b-cell lymphoma | dana-farber cancer institute
-
2:47
efficacy of epcoritamab and glofitamab in diffuse large b-cell lymphoma - blood cancers onctalk 2023
-
2:08
the current and future role of bispecifics in r/r dlbcl: epcoritamab, glofitamab & more
-
8:00
genmab and abbvie present new epcoritamab data at eha 2023
-
42:34
mantle cell lymphoma treatment (and clinical trial) | jason’s story | the patient story
-
50:46
non-hodgkin lymphoma, waldenstrom macroglobulinemia patient story - sheree | the patient story
-
10:09
understanding diffuse large b-cell lymphoma with jennifer amengual, md
-
1:53
epkinly (epcoritamab-bysp)- refractory diffuse large b-cell lymphoma (dlbcl)
-
2:25
using ctdna in lymphoma: recent advances and future directions
-
3:32
epcoritamab (epkinly), a novel bispecific antibody to target cancer cells
-
3:31
fda d.i.s.c.o. burst edition: fda approval of epkinly (epcoritamab-bysp) for relapsed or refracto...
-
1:22
dana-farber cancer institute: reid merryman, md ash 2020
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
2:03
the next generation of novel agents in development for aggressive b-cell lymphoma
-
4:22
treatment options of b-cell lymphoma: glofitamab vs. epcoritamab - blood cancer video library 2023
-
2:37
reid merryman, md on caring for patients with lymphoma or cll
-
1:38
phase ii study of epcoritamab in r/r lbcl
-
2:04
an insight into how bispecifics are changing the lymphoma treatment landscape